» Articles » PMID: 11880071

Insulin-like Growth Factor-1, Insulin-like Growth Factor Binding Protein-3, and Body Mass Index: Clinical Correlates of Prostate Volume Among Black Men

Overview
Journal Urology
Specialty Urology
Date 2002 Mar 7
PMID 11880071
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To examine the relationship between insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and body mass index and prostate volume, as a surrogate marker for benign prostatic hyperplasia, in a community-based sample of black men. Epidemiologic studies examining the role of IGF-1 and IGFBP-3 suggest that increased levels of serum IGF-1 and decreased levels of serum IGFBP-3 are associated with an increased risk of prostate cancer. Few studies have examined these factors with respect to benign prostatic hyperplasia, and these have been limited to white men.

Methods: The study population consisted of a sample of 364 black men, 40 to 79 years of age, residing in Genesee County, Michigan. Men with prostate cancer or prior prostate surgery were excluded. All subjects completed a clinical examination, which included a complete urologic examination with transrectal ultrasonography, anthropometric measurements, and serum assays for IGF-1 and IGFBP-3.

Results: Multivariable regression models demonstrated that prostate volume increased with increasing age (P <0.0001) and body mass index (P = 0.03). IGFBP-3 rather than IGF-1 was positively associated with increasing prostate volume (P = 0.003).

Conclusions: This is the largest study describing the relationships between IGF-1, IGFBP-3, and body mass index and prostate volume, and the only study in black men. Although earlier studies demonstrated an association between IGF-1 and prostate cancer risk, our findings indicate that IGFBP-3 is more relevant for prostate enlargement, suggesting that IGF-1 and IGFBP-3 may play different pathophysiologic roles in benign and malignant prostatic conditions.

Citing Articles

Modified bladder outlet obstruction index for powerful efficacy prediction of transurethral resection of prostate with benign prostatic hyperplasia.

Liu H, Tian Y, Luo G, Su Z, Ban Y, Wang Z BMC Urol. 2021; 21(1):170.

PMID: 34872539 PMC: 8650302. DOI: 10.1186/s12894-021-00937-x.


Body mass index in relation to prostate-specific antigen-related parameters.

Lin D, Liu T, Chen L, Chen Z BMC Urol. 2021; 21(1):130.

PMID: 34530776 PMC: 8447781. DOI: 10.1186/s12894-020-00746-8.


Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia.

Khan S, Wolin K, Pakpahan R, Grubb R, Colditz G, Ragard L BMC Urol. 2021; 21(1):47.

PMID: 33773592 PMC: 8005244. DOI: 10.1186/s12894-021-00816-5.


African Immigrant Health: Prostate Cancer Attitudes, Perceptions, and Barriers.

Malika N, Ogundimu O, Roberts L, Alemi Q, Casiano C, Montgomery S Am J Mens Health. 2020; 14(4):1557988320945465.

PMID: 32815480 PMC: 7444135. DOI: 10.1177/1557988320945465.


Analysis of risk factors for post-bacillus Calmette-Guerin-induced prostatitis in patients with non-muscle invasive bladder cancer.

Kim T, Yu Y, Hwang S, Lee H, Hong S, Lee S Sci Rep. 2020; 10(1):9763.

PMID: 32555265 PMC: 7300010. DOI: 10.1038/s41598-020-66952-4.